Payment overview · 2025
General Payments
$501.87
23 reported records · 10 companies
Healthcare provider profile · identity verified
Luis Antonio Vasquez, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · NEW YORK, NY · NPI 1760407084
Verified facts
What the public records show
CMS Open Payments records show Luis Antonio Vasquez, PAC received $501.87 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Rexulti, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 479 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.09 | 19.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.39 | 19.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.84 | 15.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.98 | 13.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.08 | 9.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.50 | 6.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.67 | 5.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.07 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.41 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.84 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $501.87 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.09 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.39 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.98 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $46.58 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.26 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 234 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 479 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 72 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
479 | 104 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
50 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
234 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
127 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 1493 | 305 |
| Gabapentin | Gabapentin | 1252 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 1247 | 252 |
| Simvastatin | Simvastatin | 1163 | 253 |
| Memantine Hcl | Memantine Hcl | 779 | 158 |
| Metformin Hcl | Metformin Hcl | 730 | 151 |
| Diclofenac Sodium | Diclofenac Sodium | 707 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 674 | 161 |
| Escitalopram Oxalate | Escitalopram Oxalate | 659 | 128 |
| Mirtazapine | Mirtazapine | 658 | 142 |
| Alendronate Sodium | Alendronate Sodium | 651 | 134 |
| Folic Acid | Folic Acid | 647 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 616 | 138 |
| Meclizine Hcl | Meclizine Hcl | 599 | 125 |
| Celecoxib | Celecoxib | 598 | 125 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 594 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 588 | 97 |
| Famotidine | Famotidine | 513 | 100 |
| Linzess | Linaclotide | 479 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 470 | 95 |
| Vascepa | Icosapent Ethyl | 460 | 96 |
| Carvedilol | Carvedilol | 455 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 439 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 424 | 85 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 424 | 79 |
| Glipizide | Glipizide | 423 | 88 |
| Losartan Potassium | Losartan Potassium | 366 | 83 |
| Montelukast Sodium | Montelukast Sodium | 317 | 62 |
| Dexlansoprazole Dr | Dexlansoprazole | 304 | 64 |
| Lisinopril | Lisinopril | 301 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 300 | 65 |
| Trazodone Hcl | Trazodone Hcl | 286 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 64 |
| Enalapril Maleate | Enalapril Maleate | 281 | 59 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 273 | 54 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 272 | 57 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 269 | 64 |
| Sumatriptan Succinate | Sumatriptan Succinate | 267 | 43 |
| Ezetimibe | Ezetimibe | 255 | 57 |
| Metformin Hcl Er | Metformin Hcl | 249 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 240 | 49 |
| Meloxicam | Meloxicam | 237 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 236 | 55 |
| Farxiga | Dapagliflozin Propanediol | 234 | 46 |
| Januvia | Sitagliptin Phosphate | 207 | 37 |
| Valacyclovir | Valacyclovir Hcl | 207 | 46 |
| Naproxen | Naproxen | 205 | 53 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 204 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 201 | 53 |
| Ozempic | Semaglutide | 199 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 197 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 195 | 44 |
| Icosapent Ethyl | Icosapent Ethyl | 187 | 44 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 186 | 36 |
| Single Use Swab | Alcohol Antiseptic Pads | 181 | 40 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 180 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 180 | 32 |
| Sertraline Hcl | Sertraline Hcl | 179 | 37 |
| Clobetasol Propionate | Clobetasol Propionate | 176 | 83 |
| Ammonium Lactate | Ammonium Lactate | 168 | 37 |
| Furosemide | Furosemide | 159 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 22 |
| Jardiance | Empagliflozin | 154 | 28 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 145 | 36 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 142 | 34 |
| Nifedipine Er | Nifedipine | 133 | 28 |
| Ibuprofen | Ibuprofen | 131 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 51 |
| Trulicity | Dulaglutide | 127 | 17 |
| Eliquis | Apixaban | 124 | 31 |
| Donepezil Hcl | Donepezil Hcl | 123 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 36 |
| Novolog Flexpen | Insulin Aspart | 122 | 22 |
| Rybelsus | Semaglutide | 115 | 19 |
| Hydrocortisone | Hydrocortisone | 106 | 38 |
| Ibandronate Sodium | Ibandronate Sodium | 105 | 23 |
| Metformin Er Gastric | Metformin Hcl | 96 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 95 | 17 |
| Memantine Hcl Er | Memantine Hcl | 94 | 21 |
| Dutasteride | Dutasteride | 86 | 15 |
| Finasteride | Finasteride | 82 | 18 |
| Lactulose | Lactulose | 82 | 18 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 82 | 23 |
| Latanoprost | Latanoprost | 80 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 64 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 75 | 22 |
| Brilinta | Ticagrelor | 74 | suppressed |
| Entresto | Sacubitril/Valsartan | 74 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 73 | 21 |
| Clonazepam | Clonazepam | 72 | 24 |
| Rexulti | Brexpiprazole | 72 | 18 |
| Chlorthalidone | Chlorthalidone | 70 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 18 |
| Lidocaine | Lidocaine | 69 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 67 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 19 |
| Atenolol | Atenolol | 62 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 16 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 59 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 12 |
| Nabumetone | Nabumetone | 57 | 23 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 55 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 13 |
| Olanzapine | Olanzapine | 51 | suppressed |
| Fenofibrate | Fenofibrate | 50 | 12 |
| Prolia | Denosumab | 50 | 28 |
| Restasis | Cyclosporine | 49 | 11 |
| Torsemide | Torsemide | 49 | 11 |
| Valsartan | Valsartan | 49 | 14 |
| Alprazolam | Alprazolam | 48 | 13 |
| Bupropion Hcl | Bupropion Hcl | 48 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 48 | 23 |
| Procto-Med Hc | Hydrocortisone | 45 | 19 |
| Diclofenac Potassium | Diclofenac Potassium | 43 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Myrbetriq | Mirabegron | 41 | 11 |
| Nystatin | Nystatin | 41 | 17 |
| Azithromycin | Azithromycin | 40 | 36 |
| Acetic Acid | Acetic Acid | 39 | 34 |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 32 |
| Repaglinide | Repaglinide | 38 | suppressed |
| Pregabalin | Pregabalin | 36 | 15 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Fluocinonide | Fluocinonide | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 22 |
| Mometasone Furoate | Mometasone Furoate | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 14 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Dexilant | Dexlansoprazole | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Admelog Solostar | Insulin Lispro | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 11 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | 18 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | 14 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $501.87 · 23 records | Amgen Inc. | ACCRUFER, CAPLYTA, CREON, ELIQUIS, FARXIGA, LINZESS, MOUNJARO, NURTEC ODT, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error